Rivaroxaban News and Research

RSS
Low-dose direct oral anticoagulants linked to increased bleeding risk in Afib patients

Low-dose direct oral anticoagulants linked to increased bleeding risk in Afib patients

New joint guideline highlights importance of coordinated care for peripheral artery disease

New joint guideline highlights importance of coordinated care for peripheral artery disease

Study: Most stroke survivors can safely take two types of common antidepressants

Study: Most stroke survivors can safely take two types of common antidepressants

Common oral anticoagulant rivaroxaban linked to highest risk of bleeding complications

Common oral anticoagulant rivaroxaban linked to highest risk of bleeding complications

Abelacimab significantly reduces bleeding risk in atrial fibrillation patients with stroke risk

Abelacimab significantly reduces bleeding risk in atrial fibrillation patients with stroke risk

Modern blood thinners linked to reduced risk of bleeding

Modern blood thinners linked to reduced risk of bleeding

Do system-level DOAC therapy management services affect anticoagulation outcomes for AF patients compared to usual care?

Do system-level DOAC therapy management services affect anticoagulation outcomes for AF patients compared to usual care?

Research offers a cost-effectiveness analysis of anticoagulant drugs for cancer-associated thrombosis

Research offers a cost-effectiveness analysis of anticoagulant drugs for cancer-associated thrombosis

Cost-effectiveness analysis of four interventions for treatment of cancer-associated thrombosis

Cost-effectiveness analysis of four interventions for treatment of cancer-associated thrombosis

Direct oral anticoagulants more effective and cost-effective for treating cancer-associated thrombosis

Direct oral anticoagulants more effective and cost-effective for treating cancer-associated thrombosis

Does nirmatrelvir and ritonavir reduce the risk of hospitalization or death among outpatients with early COVID-19?

Does nirmatrelvir and ritonavir reduce the risk of hospitalization or death among outpatients with early COVID-19?

No benefit of low dose apixaban following acute COVID-19

No benefit of low dose apixaban following acute COVID-19

Additional six weeks of anti-clotting treatment reduces further clot risk after distal DVT

Additional six weeks of anti-clotting treatment reduces further clot risk after distal DVT

Study explores the effect of COVID-19 on platelet function

Study explores the effect of COVID-19 on platelet function

SARS-CoV-2 infection may be a trigger of myelin oligodendrocyte glycoprotein-associated disorder

SARS-CoV-2 infection may be a trigger of myelin oligodendrocyte glycoprotein-associated disorder

Low-dose apixaban treatment reduces recurrence of venous thromboembolism compared to anticoagulant discontinuation after negative D-dimer

Low-dose apixaban treatment reduces recurrence of venous thromboembolism compared to anticoagulant discontinuation after negative D-dimer

Many treatments for intracerebral hemorrhage are not as effective as previously thought, guideline suggests

Many treatments for intracerebral hemorrhage are not as effective as previously thought, guideline suggests

Reduced kidney function caused by antithrombotic therapy can influence bleeding events

Reduced kidney function caused by antithrombotic therapy can influence bleeding events

Meta-analysis finds intensified anticoagulation had no effect on short term mortality among hospitalized COVID-19 patients

Meta-analysis finds intensified anticoagulation had no effect on short term mortality among hospitalized COVID-19 patients

Impact of atrial fibrillation in COVID-19 vaccine-induced pericarditis patients

Impact of atrial fibrillation in COVID-19 vaccine-induced pericarditis patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.